Analysts predict that Amarin Co. plc (NASDAQ:AMRN) will report $0.03 earnings per share (EPS) for the current quarter, according to Zacks Investment Research. Seven analysts have made estimates for Amarin’s earnings, with estimates ranging from $0.01 to $0.05. Amarin posted earnings of $0.01 per share in the same quarter last year, which suggests a positive year-over-year growth rate of 200%. The business is scheduled to issue its next quarterly earnings results on Tuesday, November 3rd.
According to Zacks, analysts expect that Amarin will report full year earnings of $0.06 per share for the current year, with EPS estimates ranging from $0.04 to $0.10. For the next financial year, analysts expect that the firm will post earnings of $0.27 per share, with EPS estimates ranging from ($0.31) to $0.78. Zacks’ earnings per share calculations are an average based on a survey of research firms that follow Amarin.
Amarin (NASDAQ:AMRN) last issued its earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.01 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.07) by $0.08. The company had revenue of $133.72 million for the quarter, compared to analysts’ expectations of $149.48 million. Amarin had a negative net margin of 2.30% and a negative return on equity of 2.16%. Amarin’s quarterly revenue was up 33.2% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.02 EPS.
Shares of AMRN stock traded down $0.13 on Thursday, reaching $3.88. The stock had a trading volume of 262,696 shares, compared to its average volume of 10,486,729. The firm’s 50-day moving average is $5.99 and its two-hundred day moving average is $7.44. The firm has a market capitalization of $1.55 billion, a price-to-earnings ratio of -100.25 and a beta of 2.65. Amarin has a 12 month low of $3.91 and a 12 month high of $26.12.
Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Federated Hermes Inc. boosted its position in shares of Amarin by 54.1% during the 2nd quarter. Federated Hermes Inc. now owns 5,300,300 shares of the biopharmaceutical company’s stock worth $36,678,000 after acquiring an additional 1,860,000 shares in the last quarter. Janus Henderson Group PLC boosted its position in shares of Amarin by 41.9% during the 1st quarter. Janus Henderson Group PLC now owns 5,116,756 shares of the biopharmaceutical company’s stock worth $20,467,000 after acquiring an additional 1,511,092 shares in the last quarter. Clearbridge Investments LLC boosted its position in shares of Amarin by 35.8% during the 1st quarter. Clearbridge Investments LLC now owns 2,186,201 shares of the biopharmaceutical company’s stock worth $8,745,000 after acquiring an additional 576,799 shares in the last quarter. Fairmount Funds Management LLC boosted its position in shares of Amarin by 61.0% during the 2nd quarter. Fairmount Funds Management LLC now owns 1,403,237 shares of the biopharmaceutical company’s stock worth $9,710,000 after acquiring an additional 531,523 shares in the last quarter. Finally, Pictet Asset Management Ltd. boosted its position in shares of Amarin by 40.6% during the 1st quarter. Pictet Asset Management Ltd. now owns 1,361,522 shares of the biopharmaceutical company’s stock worth $5,446,000 after acquiring an additional 393,492 shares in the last quarter. Institutional investors and hedge funds own 42.14% of the company’s stock.
Amarin Company Profile
Amarin Corp. Plc is a biopharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. Its product development program leverages its experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. It has developed and markets Vascepa capsules through wholesale.
Further Reading: Growth Stocks
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Amarin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amarin and related companies with MarketBeat.com's FREE daily email newsletter.